Rebecca White
Family · Augusta, GANPI 1396311015
Payments from drug & device makers
Across 61 payments — averaging $28.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ANI Pharmaceuticals, Inc.$445
- Otsuka America Pharmaceutical, Inc.$431
- Calliditas Therapeutics US Inc.$150
- Akebia Therapeutics Inc$136
- AstraZeneca$104
- Bayer$72
- plus $393 from 12 others
What the payments were for
- Food & beverage$1,728100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 2 | $445 |
| Otsuka America Pharmaceutical, Inc. | 16 | $431 |
| Calliditas Therapeutics US Inc. | 7 | $150 |
| Akebia Therapeutics Inc | 5 | $136 |
| AstraZeneca(2 entities) | 5 | $104 |
| Bayer | 4 | $72 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $57 |
| Boehringer Ingelheim | 3 | $57 |
| Lilly USA, LLC | 2 | $39 |
| Vifor Pharma, Inc. | 2 | $38 |
| Ardelyx, Inc. | 2 | $38 |
| Aurinia Pharma U.S., Inc. | 2 | $34 |
| Travere Therapeutics, Inc. | 3 | $26 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Merck | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| GSK | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,731 in reported general payments places this provider in the 75th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Losartan Potassium | 46 | $554 |
| Potassium Chloride | 15 | $438 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 22 | $174 |
| Hydralazine Hcl | 18 | $161 |
| Amlodipine Besylate | 27 | $145 |
| Furosemide | 33 | $96 |
| Lisinopril | 14 | $82 |
Paid to pharmacies, not to this prescriber.
Other family in Augusta
- Stephanie JacobsonAugusta$24K
- Clovalyn Jeffrey-McgannAugusta$19K
- Victoria BurtAugusta$15K
- Gloria DowneyAugusta$14K
- Joni SmithAugusta$14K
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.